

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with section 10(a)(2) of the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Immunization Practices (ACIP).

This meeting is open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is October 11, 2017. Written comments must include full name, address, organizational affiliation, email address of the speaker, topic being addressed and specific comments. Written comments must not exceed one single-spaced typed page with 1-inch margins containing all items above. Only those written comments received 10 business days in advance of the meeting will be included in the official record of the meeting. Public comments made in attendance must be no longer than 3 minutes and the person giving comments must attend the public comment session at the start time listed on the agenda. Time for public comments may start before the time indicated on the agenda. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: <http://www.cdc.gov/vaccines/acip/index.html>.

**DATES:** The meeting will be held on October 25, 2017, 8:00 a.m. to 6:00 p.m., EDT, and October 26, 2017 8:00 a.m. to 3:15 p.m. EDT.

**ADDRESSES:** 1600 Clifton Road NE., Atlanta, GA 30329, CDC, Tom Harkin Global Communications Center, Kent 'Oz' Nelson Auditorium.

**FOR FURTHER INFORMATION CONTACT:** Stephanie Thomas, ACIP Committee Management Specialist, CDC, NCIRD; email: [ACIP@cdc.gov](mailto:ACIP@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health

Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

*Matters to be Considered:* The agenda will include discussions on adult immunization schedule, child/adolescent immunization schedule, influenza vaccines, anthrax vaccine, Japanese encephalitis vaccines, hepatitis vaccines, herpes zoster vaccines, human papillomavirus vaccines, mumps vaccine, pneumococcal vaccines, respiratory syncytial virus vaccine and immunization safety update. A recommendation vote is scheduled for adult immunization schedule, child/adolescent immunization schedule, hepatitis vaccines and herpes zoster vaccines. A Vaccines for Children vote is scheduled for hepatitis vaccines. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2017-19497 Filed 9-13-17; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Pub. L. 92-463.

*Name of Committee:* Safety and Occupational Health Study Section (SOHSS), National Institute for Occupational Safety and Health (NIOSH).

*Date:* October 31–November 1, 2017.

*Time:* 8:00 a.m.–5:00 p.m., CST.

*Place:* The Wit Hotel, 201 North State Street, Chicago, Illinois 60601.

*Agenda:* The meeting will convene to address matters related to the conduct of Study Section business and for the study section to consider safety and occupational health-related grant applications.

*For Further Information Contact:* Price Connor, Ph.D., NIOSH Health Scientist, CDC 2400 Executive Parkway, Atlanta, Georgia 30345, (404) 498-2511, [spc3@cdc](mailto:spc3@cdc).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2017-19500 Filed 9-13-17; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Name of Committee:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—PAR 13-129, NIOSH Member Conflict Special Emphasis Panel.

*Date:* October 25, 2017.

*Time:* 1:00 p.m.–5:00 p.m., EDT.

*Place:* Teleconference.

*Agenda:* The meeting will include the initial review, discussion, and evaluation of applications received in response to PAR 13-129, NIOSH Member Conflict Special Emphasis Panel.

*For Further Information Contact:* Nina Turner, Ph.D. Scientific Review Officer, CDC, 1095 Willowdale Road, Morgantown, West Virginia 26506, (304) 285-5976, [nxt2@cdc.gov](mailto:nxt2@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and